MacroGenics vs Arcus Biosciences
MGNX and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGNX and RCUS compare
Arcus Biosciences is the larger company, worth 16 times as much as MacroGenics ($2.1B against $138M).
MacroGenics grew revenue faster over the last twelve months (11.7% versus −55.3% for Arcus Biosciences).
MacroGenics keeps more of each dollar of sales as profit, with a net margin of −8.7% compared with −393% at Arcus Biosciences.
MacroGenics scores higher on the StockData Score (5 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGNX | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $2.1B |
| Share price | $2.17 | $16.86 |
| Change, 1 year | 35.6% | −14.8% |
| Change, 5 years | −88.4% | −63.6% |
| Beta (5Y) | 0.45 | 1.09 |
| Employees | 293 | 601 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× (better) | 18.3× |
| P/B | 3.2× (better) | 4.6× |
| FCF yield | −47.4% | −22.1% (better) |
| Fair value | – | $7.35 |
| Margin of safety | – | −129% |
| Growth | ||
| Revenue growth (TTM) | 11.7% (better) | −55.3% |
| Revenue growth, 5Y average | 7.3% | 25.9% (better) |
| Profitability | ||
| Operating margin | −24.3% (better) | −415% |
| Net margin | −8.7% (better) | −393% |
| FCF margin | −39.1% (better) | −406% |
| Return on equity | −32.6% (better) | −90.8% |
| Financial health | ||
| Interest coverage | −2.4× (better) | −44.2× |
| Current ratio | 2.96 | 3.82 (better) |
| Altman Z-score | −4.00 | −0.67 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −13.4% |
| Shareholder yield | 0.00% (better) | −13.4% |
| Ownership | ||
| Held by institutions | 76.4% | 96.3% |
| Held by insiders | 6.2% | 31.7% |
| Insider net buying, 12 months | −$129K (better) | −$9.3M |
| Short interest, % of float | 8.3% | 15.2% |
Go deeper
- MGNX stock overview
- MGNX income statement
- MGNX valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.